Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.63 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.61 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13291593 | 0.91 | CYP4F2 (0.62) | SLC7A5CYP4F2CYP4A11LMNALOXL2 | |
| SCHEMBL23471000 | 0.88 | SLC7A5 (0.65) | SLC7A5CYP4F2CYP4A11LMNALOXL2 | |
| SCHEMBL3033016 | 0.88 | LMNA (0.66) | SLC7A5CYP4F2CYP4A11LMNALOXL2 | |
| SCHEMBL23471250 | 0.86 | SLC7A5 (0.59) | SLC7A5CYP4F2CYP4A11LOXL2TSHR | |
| SCHEMBL134602 | 0.86 | SLC7A5 (0.60) | SLC7A5CYP4F2CYP4A11LMNATSHR | |
| SCHEMBL10174728 | 0.85 | CYP4F2 (0.56) | SLC7A5CYP4F2CYP4A11LMNALOXL2 | |
| SCHEMBL19634575 | 0.85 | SLC7A5 (0.66) | SLC7A5CYP4F2CYP4A11LMNALOXL2 | |
| SCHEMBL10706157 | 0.85 | L3MBTL1 (0.57) | CYP4F2CYP4A11LMNATSHRSMN1; SMN2 | |
| SCHEMBL129801 | 0.84 | CYP4F2 (0.71) | CYP4F2CYP4A11LOXL2TSHRMEP1B | |
| SCHEMBL6537065 | 0.84 | SLC7A5 (0.59) | SLC7A5CYP4F2CYP4A11LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8148371-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-7754728-B2 | Adenine compound and use thereof | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256118-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, P2RY10, HRH4 | SLC7A5 785/4885CYP4F2 455/4885CYP4A11 24/4885 |
| US-20120178743-A1 | NOVEL ADENINE COMPOUND AND USE THEREOF | ADORA1, HRH4, P2RY10 | SLC7A5 880/4885CYP4F2 387/4885CYP4A11 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.